2008
April	Nucleonics Says USPTO Rejects All Claims For Fourth Time In Re-Exam Of Benitec’s Patent
	Nucleonics Appoints Dr. Michael D. Young as Chief Medical Officer
January	Nucleonics Initiates Hepatitis B Clinical Trial with Expressed Interfering RNA Therapeutic
2007
October	Nucleonics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
July	Nucleonics Challenges Dismissal of Counterclaims against Benitec Nucleonics Comments on US Court of Appeals Decision in Benitec v. Nucleonics
May	Nucleonics Receives FDA Clearance to Begin Phase 1 Trial of Expressed RNAi Approach to Treating Chronic Hepatitis B Infections
February	USPTO Rejects All Claims in Re-Exam of Benitec’s Patent in Response to Nucleonics’ Request for Re-Examination
2005
October	Nucleonics Plans Appeal of Courts Dismissal of Patent Infringement Litigation Brought by Benitec
March	Nucleonics Reports Granting of Two Key Patents on RNA Interference by Australian Patent Office Nucleonics Files 3rd Party Observations in Benitec's Polish Patent Prosecution
January	Nucleonics Files 3rd Party Observations in Benitec's European Patent Prosecution
2004
November	Nucleonics Challenges Validity of 3rd Benitec Patent Nucleonics Licenses Key Apath Technology for Use in Hepatitis C Therapeutic
October	Nucleonics Secures $2.7M Equipment Financing Facility Nucleonics Challenges Validity of Benitec's U.S. Patent
September	Nucleonics Challenges Validity of Benitec's Australian Patent Nucleonics Names Clinical Advisory Board
August	Nucleonics And Novosom Collaborate to Apply Novosom's SMARTICLES® Delivery Technology to Nucleonics' eiRNA Approach to Hepatitis B and C Therapeutics
June	Nucleonics Adds Additional $8.3 Million to Series B Financing, Bringing Total Raised this Round to $49.2 Million Nucleonics Licenses Key Promoter Technology for Use in RNAi Applications from the University of California
April	Nucleonics Raises $40.9 Million In Series B Venture Financing
2003
September	Nucleonics Receives NIH Grant Supporting Research Partnership Aimed at Developing RNAi Approach to Treatment of Hepatitis B Infections
August	Nucleonics Gains Rights from Wyeth Pharmaceuticals to Fundamental Gene Silencing Patent Applications Covering the Use of DNA Constructs for the Intracellular Delivery of Interfering RNAs Robert Towarnicki Named Chief Executive Officer of Nucleonics